Cargando…
Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant
HIV-1 is a chronic disease managed by strictly adhering to daily antiretroviral therapy (ART). However, not all people living with HIV-1 have access to ART, and those with access may not adhere to treatment regimens increasing viral load and disease progression. Here, a subcutaneous nanofluidic impl...
Autores principales: | Pons-Faudoa, Fernanda P., Trani, Nicola Di, Sizovs, Antons, Shelton, Kathryn A., Momin, Zoha, Bushman, Lane R., Xu, Jiaqiong, Lewis, Dorothy E., Demaria, Sandra, Hawkins, Trevor, Rooney, James F., Marzinke, Mark A., Kimata, Jason T., Anderson, Peter L., Nehete, Pramod N., Arduino, Roberto C., Sastry, K. Jagannadha, Grattoni, Alessandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590004/ https://www.ncbi.nlm.nih.gov/pubmed/33080776 http://dx.doi.org/10.3390/pharmaceutics12100981 |
Ejemplares similares
-
Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection
por: Bekerman, Elena, et al.
Publicado: (2020) -
A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil
Fumarate versus Tenofovir Alafenamide
por: Wassner, Chanie, et al.
Publicado: (2020) -
Functional Impairment of Central Memory CD4 T Cells Is a Potential
Early Prognostic Marker for Changing Viral Load in SHIV-Infected Rhesus
Macaques
por: He, Hong, et al.
Publicado: (2011) -
Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines
por: Weaver, Eric A., et al.
Publicado: (2009) -
Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
por: Funderburg, Nicholas T., et al.
Publicado: (2016)